• In December, additional analysis of the ongoing Phase 2 open-label extension study of fitusiran, an RNA interference therapeutic targeting antithrombin (AT) for patients with hemophilia A and B with and without inhibitors, was shared at the 61^st Annual Meeting of the American Society of Hematology in Orlando, Florida.
• Proof of concept was achieved for SAR439859, a selective estrogen receptor degrader (SERD), as a monotherapy in third-line metastatic breast cancer.  A pivotal study evaluating SAR439859 as a monotherapy in second and third-line metastatic breast cancer was initiated.
• Phase 2 results for SAR440340, Anti-IL33 in collaboration with Regeneron, in chronic obstructive pulmonary disease (COPD) demonstrated reduced exacerbations in the overall study population, but the results were not statistically significant.  Sanofi and Regeneron are evaluating a potential path forward in this indication.

Phase 1:

• Proof of concept was achieved for sutimlimab in patients with immune thrombocytopenic purpura (ITP) without adequate response to two or more prior therapies.  These results will be presented at the 61^st Annual Meeting of the American Society of Hematology in Orlando, Florida. ITP represents the second indication investigated for sutimlimab, an antibody molecule that could have broad utility for several complement-mediated diseases where autoantibodies attack host tissues. 

Collaboration

      · In November, Sanofi and Aetion announced an enterprise-wide collaboration that will integrate Sanofi’s real-world data platform, DARWIN, with the Aetion Evidence Platform® to advance more efficient use of real-world evidence. 

About Sanofi Capital Markets Day

Sanofi will host a Capital Markets Day in its offices in Cambridge, Massachusetts, U.S., on December 10, 2019, which will start at 9:00 am EST (2:00pm CET). The meeting will be a live webcast and can be accessed along with full copies of the presentations via the Investors Relations section of Sanofi corporate website: www.sanofi.com/investors^[2]. A replay will be available shortly after the live webcast.